One of the first questions expectant parents ask when researching cord blood banking is a simple one: what can these cells actually do? It's the right question to start with. The diseases treated with cord blood stem cells now number more than 80 — a list that has grown steadily since the first successful cord blood transplant in 1988 — and understanding what's on that list is the clearest way to evaluate whether banking makes sense for your family.
This guide covers the full landscape: established treatments backed by decades of clinical use, emerging therapies currently in research and trials, and what the science says about where cord blood medicine is headed next.
More Than 80 Diseases — and the Number Keeps Growing
Cord blood stem cells are not a niche medical curiosity. They are a clinically established treatment tool used in hospitals across the United States and around the world, with more than 40,000 cord blood transplants performed globally to date. The conditions they treat span blood cancers, inherited blood disorders, immune deficiencies, and metabolic diseases — with a growing frontier in regenerative and neurological medicine.
💡 Cord blood stem cells are a recognised treatment for more than 80 diseases and disorders. The first cord blood transplant was performed in 1988 for a child with Fanconi anemia — and that patient is still alive today.
The core reason cord blood is so therapeutically versatile is the nature of the cells it contains. Cord blood is rich in hematopoietic stem cells (HSCs) — immature cells that can develop into every type of blood cell the body produces. When a patient's own blood or immune system is diseased or destroyed by cancer treatment, a cord blood transplant can essentially reboot it. The donated or stored HSCs travel to the bone marrow, engraft, and begin generating a new, healthy blood system.
That regenerative capability is what makes cord blood relevant to such a wide range of conditions.
The Science: How Cord Blood Stem Cells Work in Treatment
To appreciate why cord blood treats such a broad category of diseases, it helps to understand what hematopoietic stem cells do. Every blood cell in your body — red blood cells, white blood cells, platelets — originates from HSCs in the bone marrow. When disease disrupts that process (as in leukemia, where abnormal white blood cells crowd out healthy ones), or when genetic mutations mean the bone marrow produces defective cells from birth (as in sickle cell disease), replacing those HSCs with healthy ones can be curative.
A cord blood transplant works by first destroying the patient's diseased bone marrow — typically through chemotherapy, radiation, or both — and then infusing the stored cord blood cells. Those cells migrate to the bone marrow, engraft, and begin producing healthy blood cells. It is, in the truest sense, a biological reset.
A 2017 study in Blood confirmed that unrelated cord blood transplantation produces outcomes comparable to matched unrelated bone marrow transplantation for many blood cancers — a finding that significantly elevated the clinical standing of cord blood as a transplant source. One important advantage cord blood holds over bone marrow is its immunological tolerance: cord blood stem cells are less mature than adult stem cells, which means they are less likely to attack the recipient's body in a complication known as graft-versus-host disease (GvHD).
A 2019 review in Stem Cell Reviews and Reports further highlighted that cord blood's lower GvHD risk makes it particularly valuable for patients who cannot find a perfectly matched bone marrow donor — a meaningful advantage given that ethnic minorities in the US often face greater difficulty finding close bone marrow matches in national registries. Cord blood's broader matching tolerance helps level that playing field.
Beyond HSCs, cord blood also contains mesenchymal stem cells (MSCs) — found in higher concentrations in cord tissue — which play a different role. MSCs are associated with tissue repair, immune modulation, and anti-inflammatory effects, and are the subject of active research in conditions ranging from cerebral palsy to autoimmune disease.
Who in the US Benefits Most from Cord Blood Banking?
In the United States, cord blood transplants are performed at major academic medical centres and children's hospitals across the country. Families from all backgrounds bank cord blood, but several groups have particularly compelling reasons to consider it.
- Families with a history of blood disorders. If your family has a history of sickle cell disease, thalassemia, or inherited bone marrow failure syndromes, banking your newborn's cord blood provides a potentially life-saving resource — both for that child and for existing siblings who may already be affected.
- Families from ethnic minority backgrounds. As noted above, patients of African American, Hispanic, Asian, and mixed heritage face statistically lower odds of finding a close match in the bone marrow registry. A 2014 analysis in JAMA found that while white patients had over a 75% chance of finding a suitably matched unrelated donor, that figure dropped significantly for patients of African American descent. A privately banked cord blood unit sidesteps the registry entirely for the stored child and offers a potential match for siblings.
- Any family planning ahead. Most families who bank cord blood are not doing so because they expect to need it — they're doing so because they want the option. Stem cell medicine is one of the fastest-moving fields in healthcare. The list of treatable conditions in 2026 is meaningfully longer than it was in 2010, and the list in 2036 is likely to be longer still.
The Full Disease List: Established and Emerging Conditions
Blood Cancers (Established)
These are the most clinically established uses of cord blood stem cells, with decades of transplant data supporting their efficacy:
-
Acute Myeloid Leukemia (AML)
-
Acute Lymphoblastic Leukemia (ALL)
-
Chronic Myelogenous Leukemia (CML)
-
Chronic Lymphocytic Leukemia (CLL)
-
Hodgkin Lymphoma
-
Non-Hodgkin Lymphoma
-
Juvenile Myelomonocytic Leukemia (JMML)
-
Myelodysplastic Syndromes (MDS)
-
Multiple Myeloma
Inherited Blood and Bone Marrow Disorders (Established)
-
Sickle Cell Disease
-
Beta-Thalassemia and other thalassemias
-
Fanconi Anemia
-
Diamond-Blackfan Anemia
-
Aplastic Anemia (severe)
-
Kostmann Syndrome
-
Congenital Amegakaryocytic Thrombocytopenia
-
Shwachman-Diamond Syndrome
-
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immune Deficiencies (Established)
-
Severe Combined Immunodeficiency (SCID) — including all subtypes
-
Wiskott-Aldrich Syndrome
-
Chronic Granulomatous Disease
-
Leukocyte Adhesion Deficiency
-
Chediak-Higashi Syndrome
-
Omenn Syndrome
-
Cartilage-Hair Hypoplasia
Metabolic and Storage Disorders (Established)
Cord blood transplantation is an established treatment for a range of lysosomal storage and metabolic diseases, particularly when performed early in the course of disease:
-
Hurler Syndrome (MPS I)
-
Hunter Syndrome (MPS II)
-
Krabbe Disease (Globoid Cell Leukodystrophy)
-
Metachromatic Leukodystrophy (MLD)
-
Gaucher Disease (Type III)
-
Niemann-Pick Disease (Type B)
-
Adrenoleukodystrophy (ALD)
-
Sanfilippo Syndrome (MPS III)
-
Mucolipidosis II
-
Wolman Disease
Emerging Research Areas
The following conditions are the subject of active clinical trials and peer-reviewed research. They are not yet standard-of-care uses, but the early data is generating genuine clinical interest:
- Cerebral Palsy. Several trials at Duke University have investigated autologous cord blood infusion — using a child's own stored cord blood — in children with cerebral palsy, with early results suggesting improvements in motor function in some patients. A 2017 trial published in Stem Cells led by Dr. Joanne Kurtzberg found that autologous cord blood infusion was safe and associated with improved brain connectivity and motor outcomes in children with cerebral palsy.
- Autism Spectrum Disorder (ASD). Duke University researchers have also explored autologous cord blood infusion for children with ASD, with a 2020 study in Nature Medicine reporting that a subset of children showed improvements in socialization and communication following infusion.
- Type 1 Diabetes. Researchers are exploring whether cord blood stem cells can help preserve insulin-producing beta cells in children newly diagnosed with Type 1 diabetes. Early-phase trials are ongoing.
- Hypoxic-Ischemic Encephalopathy (HIE). Neonatal brain injury caused by oxygen deprivation at or around birth is being studied as a potential target for early cord blood infusion, with the goal of limiting long-term neurological damage.
- Hearing Loss. Pilot studies have investigated the use of autologous cord blood cells for acquired sensorineural hearing loss in young children, with some positive early signals.
It's worth noting: for autologous applications (using a child's own stored cells), private banking is the only path. The public cord blood registry does not store blood for individual family use.
How AlphaCord Protects Your Family's Stem Cell Investment
Understanding the disease list is one part of the picture. The other is choosing a bank you can actually trust to preserve those cells correctly — because cells that aren't processed and stored properly won't perform when they're needed.
AlphaCord has been doing this work since 2002, founded by parents who believed every American family deserved access to high-quality cord blood banking without a prohibitive price tag. Here's what backs that commitment today:
- AABB Accreditation. AlphaCord is fully AABB accredited — the highest independent quality standard in the cord blood banking industry. AABB accreditation requires rigorous inspection of processing protocols, laboratory practices, staff training, and quality management systems. It is not automatic, and it is not permanent — banks must maintain standards to keep it.
- FDA Registration. AlphaCord is FDA registered, meaning it meets federal standards for the collection, processing, storage, and distribution of human cellular tissue products.
- The $85,000 Engraftment Guarantee. AlphaCord backs its processing quality with a financial commitment: if stored cord blood cells fail to engraft in a medically eligible transplant, AlphaCord's engraftment guarantee provides up to $85,000 in financial protection. It's a statement of confidence in the work the lab does every day.
- The 3-in-1 Collection Kit. AlphaCord's collection kit captures cord blood, cord tissue, and placental tissue in a single collection procedure at birth — three stem cell sources, one opportunity, no additional complexity. Cord tissue MSCs and placental cells are the focus of growing regenerative medicine research, meaning your family banks for today's established treatments and tomorrow's emerging ones simultaneously.
- The 5-Chamber Storage Bag. Your cord blood is stored in five separate compartments. If a transplant is ever needed, only one compartment is used — leaving the rest preserved for future use. A single collection can potentially support multiple treatments over a lifetime.
- Pricing that works for real families. Cord blood banking with AlphaCord starts from just $81 per month. The complete 3-in-1 package — cord blood, cord tissue, and placental tissue — starts from $142 per month. No hidden fees. No fine print that makes quality inaccessible.
Frequently Asked Questions
Can cord blood treat diseases in siblings, not just the baby? Yes. Cord blood stem cells can be used by the child from whom they were collected (autologous use) or by a biologically compatible family member — most commonly a sibling (allogeneic use). Sibling transplants account for a significant proportion of cord blood transplants. The closer the biological match, the better the compatibility, and full siblings have the highest likelihood of matching.
What's the difference between cord blood, cord tissue, and placental tissue banking? Cord blood contains hematopoietic stem cells (HSCs) — the type used in established transplant medicine for blood cancers and disorders. Cord tissue contains mesenchymal stem cells (MSCs), which are under research for tissue repair, autoimmune conditions, and neurological applications. Placental tissue is an additional source of MSCs and other perinatal cells. AlphaCord's 3-in-1 kit captures all three in a single collection.
Is there a time limit on how long cord blood can be stored? Cord blood stored in cryogenic conditions — below -196°C in liquid nitrogen — is thought to remain viable indefinitely, based on the science of cryopreservation. Studies on cells stored for 20+ years show no meaningful degradation in viability. AlphaCord offers both annual storage plans and long-term prepaid plans to suit different families' needs.
How does AlphaCord's pricing compare to other US cord blood banks? AlphaCord is consistently among the most affordable full-service cord blood banks in the United States, with pricing starting from $81 per month for cord blood banking. Critically, affordability is not achieved by cutting corners — AlphaCord maintains AABB accreditation and FDA registration and backs its processing with an $85,000 engraftment guarantee.
Give Your Family the Option That Matters Most
The list of diseases treated with cord blood stem cells is long, and it's getting longer. From leukemia to cerebral palsy research, from sickle cell disease to emerging trials in autism and Type 1 diabetes, cord blood stem cells represent one of the most dynamic and promising frontiers in modern medicine.
You can't go back and collect what you didn't save. But right now — before your baby arrives — you have a window to preserve a biological resource that could matter enormously. AlphaCord makes that decision straightforward: AABB-accredited processing, an $85,000 engraftment guarantee, a 3-in-1 collection kit, and pricing that starts at $81 per month.
Founded by parents, trusted by families across America for over two decades.
